
Kymera: Data Derisks Platform, But I Will Wait For More (NASDAQ:KYMR)
naphtalina/iStock via Getty Images I covered Kymera Therapeutics, Inc. (NASDAQ:KYMR) in November, when it was on the verge of publishing critical proof of concept phase 1 trial data from its protein degrader platform, the particular […]